Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y(12) Assay in Patients With Coronary Artery Disease

Background: Vonoprazan is a potassium-competitive acid blocker increasingly used in Japan to prevent upper gastrointestinal bleeding in patients undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Cytochrome P450 (CYP) 3A4 is involved in the primary metabolism...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Seiji, Ikeda, Satoshi, Akashi, Ryohei, Yonekura, Tsuyoshi, Kawano, Hiroaki, Maemura, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939790/
https://www.ncbi.nlm.nih.gov/pubmed/33693287
http://dx.doi.org/10.1253/circrep.CR-20-0124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939790/
https://www.ncbi.nlm.nih.gov/pubmed/33693287
http://dx.doi.org/10.1253/circrep.CR-20-0124

Ejemplares similares